Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis

Br J Psychiatry. 2017 Jun;210(6):403-407. doi: 10.1192/bjp.bp.116.195826. Epub 2017 Apr 6.

Abstract

BackgroundKetamine has emerged as a novel therapeutic agent for major depressive episodes, spurring interest in its potential to augment electroconvulsive therapy (ECT).AimsWe sought to update our preliminary systematic review and meta-analysis, focusing on randomised controlled trials (RCTs) involving an index course of ECT, and testing the hypothesis that lack of efficacy is due to barbiturate anaesthetic co-administration.MethodWe searched EMBASE, CENTRAL and Medline to identify RCTs examining the efficacy of ketamine during a course of ECT. Data were synthesised from ten trials (ketamine group n = 333, comparator group n = 269) using pooled random effects models.ResultsElectroconvulsive therapy with ketamine was not associated with greater improvements in depressive symptoms or higher rates of clinical response or remission, nor did it result in pro-cognitive effects. This held true when limiting analysis to trials without barbiturate anaesthetic co-administration. Increased rates of confusion were reported.ConclusionsOverall, our analyses do not support using ketamine over other induction agents in ECT.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Combined Modality Therapy
  • Confusion / chemically induced
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / therapy*
  • Electroconvulsive Therapy*
  • Humans
  • Ketamine / adverse effects
  • Ketamine / therapeutic use*

Substances

  • Ketamine